Scholar Rock Holdings Corporation (SRRK) Actualités

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal...

Form 8-K - Current report

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Apitegromab met primary endpoint with statistically significant and clinically meaningful improvement in motor function as measured by the gold...

Form 4 - Statement of changes in beneficial ownership of securities

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular...

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Topline results expected in 2Q 2025 Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative...

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...

Form 4 - Statement of changes in beneficial ownership of securities

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

- Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024 - New...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...